{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:45:37Z","timestamp":1789544737507,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,12,11]],"date-time":"2012-12-11T00:00:00Z","timestamp":1355184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s00520-012-1683-5","type":"journal-article","created":{"date-parts":[[2012,12,10]],"date-time":"2012-12-10T06:50:58Z","timestamp":1355122258000},"page":"1415-1419","source":"Crossref","is-referenced-by-count":27,"title":["Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence"],"prefix":"10.1007","volume":"21","author":[{"given":"M. S.","family":"Soyfoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Paesmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,11]]},"reference":[{"key":"1683_CR1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.semnephrol.2003.08.015","volume":"24","author":"JJ Body","year":"2004","unstructured":"Body JJ (2004) Hypercalcemia of malignancy. Semin Nephrol 24:48\u201354","journal-title":"Semin Nephrol"},{"key":"1683_CR2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1210\/jc.74.3.471","volume":"74","author":"JJ Body","year":"1992","unstructured":"Body JJ, Delmas PD (1992) Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 74:471\u2013475","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt 1","key":"1683_CR3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/000456329903600117","volume":"36","author":"KU Toori","year":"1999","unstructured":"Toori KU, Bone MF, Labib MH (1999) Raised urinary pyridinium cross-links in humoral hypercalcaemia of malignancy. Ann Clin Biochem 36(Pt 1):107\u2013108","journal-title":"Ann Clin Biochem"},{"key":"1683_CR4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1210\/jcem-73-6-1309","volume":"73","author":"V Grill","year":"1991","unstructured":"Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, Moseley JM, Martin TJ (1991) Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 73:1309\u20131315","journal-title":"J Clin Endocrinol Metab"},{"key":"1683_CR5","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2006.12.006","volume":"43","author":"JJ Body","year":"2007","unstructured":"Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M (2007) International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 43:852\u2013858","journal-title":"Eur J Cancer"},{"key":"1683_CR6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0029-1241821","volume":"42","author":"L Santarpia","year":"2010","unstructured":"Santarpia L, Koch CA, Sarlis NJ (2010) Hypercalcemia in cancer patients: pathobiology and management. Horm Metab Res 42:153\u2013164","journal-title":"Horm Metab Res"},{"key":"1683_CR7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/jbmr.5650080608","volume":"8","author":"JJ Body","year":"1993","unstructured":"Body JJ, Dumon JC, Thirion M, Cleeren A (1993) Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy. J Bone Miner Res 8:701\u2013706","journal-title":"J Bone Miner Res"},{"key":"1683_CR8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s005200050008","volume":"8","author":"JJ Body","year":"2000","unstructured":"Body JJ, Louviaux I, Dumon JC (2000) Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Support Care Cancer 8:398\u2013404","journal-title":"Support Care Cancer"},{"key":"1683_CR9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/oxfordjournals.annonc.a058841","volume":"5","author":"JJ Body","year":"1994","unstructured":"Body JJ, Dumon JC (1994) Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose\u2013response relationship and influence of tumour type. Ann Oncol 5:359\u2013363","journal-title":"Ann Oncol"},{"key":"1683_CR10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0009-8981(00)00403-4","volume":"305","author":"SJ Kim","year":"2001","unstructured":"Kim SJ, Shiba E, Maeda I, Yoshioka T, Amino N, Noguchi S (2001) Screening for primary hyperparathyroidism (PHPT) in clinic patients: differential diagnosis between PHPT and malignancy-associated hypercalcemia by routine blood tests. Clin Chim Acta 305:35\u201340","journal-title":"Clin Chim Acta"},{"key":"1683_CR11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0009-8981(99)00181-3","volume":"290","author":"JL Motellon","year":"2000","unstructured":"Motellon JL, Javort Jimenez F, de Miguel F, Jaras MJ, Diaz A, Hurtado J, Esbrit P (2000) Parathyroid hormone-related protein, parathyroid hormone, and vitamin D in hypercalcemia of malignancy. Clin Chim Acta 290:189\u2013197","journal-title":"Clin Chim Acta"},{"key":"1683_CR12","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(80)91783-3","volume":"1","author":"GR Mundy","year":"1980","unstructured":"Mundy GR, Cove DH, Fisken R (1980) Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet 1:1317\u20131320","journal-title":"Lancet"},{"key":"1683_CR13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2265.1994.tb02569.x","volume":"41","author":"J Walls","year":"1994","unstructured":"Walls J, Ratcliffe WA, Howell A, Bundred NJ (1994) Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcaemia in two hospital populations. Clin Endocrinol (Oxf) 41:407\u2013413","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1683_CR14","doi-asserted-by":"crossref","first-page":"6316","DOI":"10.1210\/jc.2005-0675","volume":"90","author":"TP Jacobs","year":"2005","unstructured":"Jacobs TP, Bilezikian JP (2005) Clinical review: rare causes of hypercalcemia. J Clin Endocrinol Metab 90:6316\u20136322","journal-title":"J Clin Endocrinol Metab"},{"key":"1683_CR15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0954-6820.1986.tb02795.x","volume":"220","author":"CP Blomqvist","year":"1986","unstructured":"Blomqvist CP (1986) Malignant hypercalcemia\u2014a hospital survey. Acta Med Scand 220:455\u2013463","journal-title":"Acta Med Scand"},{"key":"1683_CR16","first-page":"405","volume":"49","author":"RA Fisken","year":"1980","unstructured":"Fisken RA, Heath DA, Bold AM (1980) Hypercalcaemia\u2014a hospital survey. Q J Med 49:405\u2013418","journal-title":"Q J Med"},{"key":"1683_CR17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/bjc.1995.304","volume":"72","author":"PJ Ling","year":"1995","unstructured":"Ling PJ, A\u2019Hern RP, Hardy JR (1995) Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer 72:206\u2013209","journal-title":"Br J Cancer"},{"key":"1683_CR18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9343(93)90282-T","volume":"95","author":"SR Nussbaum","year":"1993","unstructured":"Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE (1993) Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 95:297\u2013304","journal-title":"Am J Med"},{"key":"1683_CR19","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1136\/bmj.288.6428.1405","volume":"288","author":"SH Ralston","year":"1984","unstructured":"Ralston SH, Fogelman I, Gardiner MD, Boyle IT (1984) Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. Br Med J 288:1405\u20131408","journal-title":"Br Med J"},{"key":"1683_CR20","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1210\/jc.84.10.3545","volume":"84","author":"R Rizzoli","year":"1999","unstructured":"Rizzoli R, Thiebaud D, Bundred N, Pecherstorfer M, Herrmann Z, Huss HJ, Ruckert F, Manegold C, Tubiana-Hulin M, Steinhauer EU, Degardin M, Thurlimann B, Clemens MR, Eghbali H, Body JJ (1999) Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab 84:3545\u20133550","journal-title":"J Clin Endocrinol Metab"},{"key":"1683_CR21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/clinchem\/37.2.162","volume":"37","author":"DB Endres","year":"1991","unstructured":"Endres DB, Villanueva R, Sharp CF Jr, Singer FR (1991) Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 37:162\u2013168","journal-title":"Clin Chem"},{"key":"1683_CR22","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1210\/jc.74.6.1385","volume":"74","author":"JJ Body","year":"1992","unstructured":"Body JJ, Dumon JC, Seraj F, Cleeren A (1992) Recovery of parathyroid hormone secretion during correction of tumor-associated hypercalcemia. J Clin Endocrinol Metab 74:1385\u20131388","journal-title":"J Clin Endocrinol Metab"},{"key":"1683_CR23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","volume":"352","author":"AF Stewart","year":"2005","unstructured":"Stewart AF (2005) Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352:373\u2013379","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1683-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-012-1683-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1683-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T10:16:43Z","timestamp":1595067403000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-012-1683-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,11]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["1683"],"URL":"https:\/\/doi.org\/10.1007\/s00520-012-1683-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,11]]}}}